SCS Boomerangs Back: Q221 Market Report

A big boost in Q2 with double-digit gains in all segments.

The US and WW SCS Market boomeranged to pre-COVID levels in Q221 driven by declining COVID-19 cases and ongoing launches of new technologies and products. With easy comps against a quarter that was one of the hardest hit by the pandemic in 2020, Q221 growth was up in the double digits vs Q220 and was up in the low-single digits compared to Q219.

Among the many topics covered in detail in our comprehensive Q221 SCS Market Recap* are:

• Complete Q221 SCS Market Overview
• SmartTRAK's Expert Analysis and Insights
• All SCS Market News including Revenues, Data, Charts and Shares
• BSX Accelerates on New Products, Evidence
• Abbott Close to Pre-Pandemic Performance
• Medtronic Sees Strong Product Uptake
• Nevro Up but Cautious on COVID-19 Headwinds
• Other Important News including Studies, Patents and Trials

Despite a strong Q221, SCS revenues could look very different in Q321 as companies reported seeing a slow down in physician visits, elective procedures and SCS trials starting in July in regions with low vaccination rates driven by ...

Read the entire Q221 SCS Market Recap, including news, data, charts, company revenues, shares and our expert analysis*